Episode Details

PTCE aims to present the most updated information available. In November 2023, the US FDA approved the first orally administered, γ-secretase inhibitor therapy, nirogacestat (Ogsivo), for the treatment of adult patients with desmoid tumors. Please refer to the prescribing information for additional information.

Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education.

Challenges in Treatment of Desmoid Tumors and Managed Care Solutions

Educational Objectives

• Recall the key characteristics of desmoid tumors (DT), including presentation, frequency, genetic mutations, development, and outlook for individual patients
• Outline practical solutions to improve managed care-driven communication with health care providers and address the clinical and financial burden of unresectable, recurrent DT

Laura Bobolts, PharmD, BCOP

Senior Vice President of Clinical Strategy and Growth

OncoHealth

Plantation, Florida

Faculty:

Christy Harris, PharmD, BCOP, FHOPA    

Clinical Pharmacy Specialist                                                               

Dana-Farber Cancer Institute

Associate Professor

Massachusetts College of Pharmacy and Health Sciences

Boston, Massachusetts

Christy Harris, PharmD, BCOP, FHOPA and Laura Bobolts, PharmD, BCOP have no financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-23-421-H01-P. The activity is available for CE credit through November 30, 2024.

This activity is supported by an educational grant from SpringWorks Therapeutics.